Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction. We show 21 historical shares outstanding datapoints in our KNSA shares outstanding history coverage, used to compute KNSA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing KNSA market cap history over the course of time is important for investors
interested in comparing KNSA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of KNSA versus a peer is one thing; comparing
KNSA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like KNSA can fluctuate over the course of history.
With this page we aim to empower investors researching KNSA by allowing them to research the KNSA market cap history. |
Free KNSA Email Alerts:
Video: The Importance of Market Cap
